WO2005023848A3 - Epitopes adenoviraux - Google Patents
Epitopes adenoviraux Download PDFInfo
- Publication number
- WO2005023848A3 WO2005023848A3 PCT/GB2004/003861 GB2004003861W WO2005023848A3 WO 2005023848 A3 WO2005023848 A3 WO 2005023848A3 GB 2004003861 W GB2004003861 W GB 2004003861W WO 2005023848 A3 WO2005023848 A3 WO 2005023848A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adenoviral
- fragment
- epitope
- region
- molecules
- Prior art date
Links
- 239000012634 fragment Substances 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20040768408 EP1664099A2 (fr) | 2003-09-09 | 2004-09-09 | Epitopes adenoviraux |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0321063A GB0321063D0 (en) | 2003-09-09 | 2003-09-09 | Adenoviral epitopes |
GB0321063.0 | 2003-09-09 | ||
GB0321179.4 | 2003-09-10 | ||
GB0321179A GB0321179D0 (en) | 2003-09-10 | 2003-09-10 | Adenoviral epitopes |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005023848A2 WO2005023848A2 (fr) | 2005-03-17 |
WO2005023848A3 true WO2005023848A3 (fr) | 2005-12-01 |
Family
ID=34276832
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2004/003861 WO2005023848A2 (fr) | 2003-09-09 | 2004-09-09 | Epitopes adenoviraux |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1664099A2 (fr) |
WO (1) | WO2005023848A2 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102089121B1 (ko) | 2013-03-14 | 2020-03-13 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양살상형 아데노바이러스 조성물 |
CL2016000164A1 (es) * | 2016-01-21 | 2016-07-29 | Pontificia Universidad Católica De Chile | Anticuerpos monoclonales específicos para el antígeno piii de adenovirus humano (adv), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por adv. |
EP3390645B1 (fr) | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Expression d'un gène exogene d'un adenovirus therapeutique avec impact minimaire sur la cinetique virale |
JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
JP2019536468A (ja) | 2016-12-12 | 2019-12-19 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 腫瘍を標的にする合成アデノウイルスおよびその使用 |
EP3715374A1 (fr) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Composé de séquestration d'anticorps indésirables chez un patient |
US11986536B2 (en) | 2019-03-23 | 2024-05-21 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
JP2022546603A (ja) * | 2019-09-04 | 2022-11-04 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 多発性硬化症に対する交差反応性エピトープ |
KR20230074775A (ko) | 2020-09-23 | 2023-05-31 | 아블레비아 바이오테크 게엠베하 | 바이러스 벡터의 효능 증가를 위한 화합물 |
WO2023180502A1 (fr) | 2022-03-24 | 2023-09-28 | Ablevia Biotech Gmbh | Composé pour augmentation de l'efficacité des virus oncolytiques |
-
2004
- 2004-09-09 WO PCT/GB2004/003861 patent/WO2005023848A2/fr not_active Application Discontinuation
- 2004-09-09 EP EP20040768408 patent/EP1664099A2/fr not_active Withdrawn
Non-Patent Citations (8)
Title |
---|
CHROBOCZEK ET AL: "THE SEQUENCE OF THE GENOME OF ADENOVIRUS TYPE 5 AND ITS COMPARISON WITH THE GENOME OF ADENOVIRUS TYPE 2", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 186, 1992, pages 280 - 285, XP002126551, ISSN: 0042-6822 * |
DATABASE EMBL [online] 22 April 1989 (1989-04-22), "Adenovirus type 5 IIIa protein, 3' end; penton base protein gene, complete cds; and VIII protein, 5' end.", XP002341884, retrieved from EBI Database accession no. M22141 * |
GAHERY-SEGARD H ET AL: "Immune reponse to recombinant capsid proteins of adenovirus in humans: Antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 72, no. 3, March 1998 (1998-03-01), pages 2388 - 2397, XP002136355, ISSN: 0022-538X * |
HABIB N ET AL: "Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma", CANCER GENE THERAPY 2002 UNITED STATES, vol. 9, no. 3, 2002, pages 254 - 259, XP002337621, ISSN: 0929-1903 * |
HABIB NAGY A ET AL: "E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors", HUMAN GENE THERAPY, vol. 12, no. 3, 10 February 2001 (2001-02-10), pages 219 - 226, XP002337622, ISSN: 1043-0342 * |
HONG SAW SEE ET AL: "Identification of adenovirus (Ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative Ad (Addl1520) for treatment of liver tumors.", JOURNAL OF VIROLOGY, vol. 77, no. 19, October 2003 (2003-10-01), pages 10366 - 10375, XP002341790, ISSN: 0022-538X * |
NEUMANN R ET AL: "DETERMINATION OF THE NUCLEOTIDE SEQUENCE FOR THE PENTON-BASE GENE OF HUMAN ADENOVIRUS TYPE 5", GENE (AMSTERDAM), vol. 69, no. 1, 1988, pages 153 - 157, XP002341791, ISSN: 0378-1119 * |
SAW SEE HONG ET AL: "IMMUNOREACTIVE DOMAINS AND INTEGRIN-BINDING MOTIFS IN ADENOVIRUS PENTON BASE CAPSOMER", VIRAL IMMUNOLOGY, MARY ANN LIEBERT, INC., NEW YORK, US, vol. 13, no. 3, 2000, pages 353 - 371, XP009041783, ISSN: 0882-8245 * |
Also Published As
Publication number | Publication date |
---|---|
EP1664099A2 (fr) | 2006-06-07 |
WO2005023848A2 (fr) | 2005-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008140812A3 (fr) | Compositions et procédés comprenant des antigènes klk3, psca ou folh1 | |
WO2009117656A3 (fr) | Antigène incorporé dans la capside pour nouveau vaccin à adénovirus | |
WO2006104677A3 (fr) | Anticorps se liant a ov064 et leurs methodes d'utilisation | |
WO2002053703A3 (fr) | Vecteurs aav2 et procedes | |
IL210378A0 (en) | Tumor associated antigen, peptides thereof, and use of same as ati-tumor vaccines | |
WO2007106476A3 (fr) | Compositions et procédés pour renforcer l'immunogénicité d'antigènes | |
WO2004074455A3 (fr) | Variants de la region fc | |
WO2005047860A3 (fr) | Anticorps a l'alpha-synucleine | |
WO2006046978A3 (fr) | Transformation par l'intermediaire de peptides cationiques | |
WO2007067730A3 (fr) | Anticorps monoclonaux humains contre la proteine tyrosine kinase 7 (ptk7) et procedes pour utiliser des anticorps anti-ptk7 | |
WO2001085932A3 (fr) | Polypeptides immunogeniques codes par des minigenes mage et leurs utilisations | |
AU2003295502A1 (en) | Adenoviral vector vaccine | |
WO2008020335A3 (fr) | Compositions immunogènes pour streptococcus agalactiae | |
WO2006081007A3 (fr) | Utilisation de flagelline en immunotherapie antitumorale | |
WO2006028429A3 (fr) | Peptide pour cibler l'antigene prostatique membranaire specifique | |
WO2004093808A3 (fr) | Nouveaux antigenes associes a une tumeur | |
WO2005030793A3 (fr) | Anticorps se liant aux cxcr3 humains | |
WO2005023848A3 (fr) | Epitopes adenoviraux | |
WO2008040190A8 (fr) | Petits peptides pour anti-angiogenèse et utilisation de ceux-ci | |
WO2004031210A3 (fr) | Constructions optimisees a plusieurs epitopes et utilisations de ces dernieres | |
WO2002098456A3 (fr) | Antigenes et vecteurs utilises pour la vaccination | |
WO2006110240A3 (fr) | Transfert de genes au moyen d'adenovirus presentant des proteines fibres modifiees | |
WO2007050128A3 (fr) | Vecteurs adenoviraux proteges et leurs methodes d'utilisation | |
WO2002036627A3 (fr) | Interferons, utilisations et compositions associees | |
WO2002102316A3 (fr) | Histone-deacetylase et procedes d'utilisation correspondants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004768408 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004768408 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004768408 Country of ref document: EP |